MedTrace Logo

FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

NCT02359357 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2016-04-08

No results posted yet for this study

Summary

To determine the safety and tolerability of single and multiple escalating doses of FDL169 in healthy male subjects.

Conditions

Interventions

DRUG

FDL169

DRUG

Placebo

Sponsors & Collaborators

  • Flatley Discovery Lab LLC

    lead OTHER

Principal Investigators

  • Salvatore Febbraro, MD · Simbec Research

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02359357 on ClinicalTrials.gov